UNSPSC 51132241: Caffeine/phenacetin/salicylamide/styramate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

UNSPSC 51132241 Caffeine/phenacetin/salicylamide/styramate is a Commodity code that shows a significant mismatch between its nominal scope and the work actually being solicited under it in state and local procurement. Recent opportunities tagged to this code are soliciting naloxone and drug deactivation systems (Seminole County, Florida), therapeutic pharmacy initiative prescriptions and direct-to-manufacturer contracting (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance / MMCAP). None of these solicitations involve the specific combination of active pharmaceutical ingredients that the code nominally describes. The code appears to be used as a catch-all for pharmaceutical procurement across health departments and cooperative purchasing organizations, rather than as a precise taxonomic marker for a defined product line.

Recent opportunities span state health agencies, county public health departments, and multistate cooperative purchasing vehicles. The Seminole County IFB (IFB60459723LAS, due July 26, 2026 — though the source shows an internal date inconsistency) targets naloxone and drug deactivation systems with 1,900 units and 800 systems annually on a two-year initial term plus one-year renewal. The Texas HHS Commission issued an RFI (HHS0017013, response due April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. MMCAP administered an RFP (S1070000015802, due March 26, 2026) for generic pharmaceuticals and OTC products across Minnesota and Oregon, requiring NDC-specific submissions to three authorized wholesalers with awards effective July 1, 2026 and performance penalties of $200 to $1,500 per violation. The code sees activity concentrated in Florida, Texas, and the upper Midwest, with cooperative purchasing reaching multiple participating jurisdictions. Vendors pursuing this code should recognize that tagging practice does not align with the code's nominal scope; success depends on understanding the actual pharmaceutical categories being bought (naloxone, generics, OTC, direct-to-manufacturer channels) rather than the code name alone.